A clinical cohort trial of antifungal combination therapy: Efficacy and toxicity in haematological cancer patients

Annals of Hematology

Volumn 87, Issue 11, 2008, Pages 915-922

  Rieger, Christina T ^a   Ostermann, Helmut ^a   Kolb, Hans Jochem ^a   Fiegl, Michael ^b   Huppmann, Saskia ^a   Morgenstern, Nicole ^a   Tischer, Johanna ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antifungal combination therapy; Efficacy; Haematological malignancy; Invasive fungal infection; Mortality; Toxicity

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CORTICOSTEROID; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAFT VERSUS HOST REACTION; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY PREVENTION; SIDE EFFECT; TREATMENT DURATION;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYCOSES; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 53649100394     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0534-4     Document Type: Article

References (36)

1. Aliff TB, Maslak PG, Jurcic JG et al (2003) Refractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97:1025-1032 doi: 10.1002/cncr.11115
2. Arikan S, Lozano-Chiu M, Paetznick V et al (2002) In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 46:245-247 doi: 10.1128/AAC.46.1.245-247.2002
3. Ascioglu S, Rex JH, de Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 34:7-14 doi: 10.1086/323335
4. Barchiesi F, Spreghini E, Tomassetti S et al (2007) Caspofungin in combination with amphotericin B against Candida parapsilosis. Antimicrob Agents Chemother 51:941-945 doi: 10.1128/AAC.00880-06
5. Bhatti Z, Shaukat A, Almyroudis NG et al (2006) Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 162:1-15 doi: 10.1007/s11046-006-0025-x
6. Bodey G, Bueltmann B, Duguid W et al (1992) Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 11:99-109 doi: 10.1007/BF01967060
7. Bodey GP, Mardani M, Hanna HA et al (2002) The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 112:380-385 doi: 10.1016/S0002-9343(01)01130-5
8. Bowman JC, Hicks PS, Kurtz MB et al (2002) The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 46:3001-3012 doi: 10.1128/ AAC.46.9.3001-3012.2002
9. Caillot D, Thiebaut A, Herbrecht R et al (2007) Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: A randomized pilot study (Combistrat trial). Cancer 110:2740-2746 doi: 10.1002/cncr.23109
10. Clemons KV, Espiritu M, Parmar R et al (2005) Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 49:4867-4875 doi: 10.1128/ AAC.49.12.4867-4875.2005
11. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G et al (2005) Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 49:1232-1235 doi: 10.1128/ AAC.49.3.1232-1235.2005
12. Denning DW, Marinus A, Cohen J et al (1998) An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 37:173-180 doi: 10.1016/S0163-4453(98)80173-4
13. Denning DW, Marr KA, Lau WM et al (2006) Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53:337-349 doi: 10.1016/ j.jinf.2006.03.003
14. Graybill JR, Bocanegra R, Gonzalez GM et al (2003) Combination antifungal therapy of murine aspergillosis: Liposomal amphotericin B and micafungin. J Antimicrob Chemother 52:656-662 doi: 10.1093/jac/dkg425
15. Groll AH, Shah PM, Mentzel C et al (1996) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33:23-32 doi: 10.1016/S0163-4453(96)92700-0
16. Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415 doi: 10.1056/NEJMoa020191
17. Jantunen E, Ruutu P, Niskanen L et al (1997) Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 19:801-808 doi: 10.1038/sj.bmt.1700737
18. Jantunen E, Ruutu P, Piilonen A et al (2000) Treatment and outcome of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 26:759-762 doi: 10.1038/sj.bmt.1702604
19. Kirkpatrick WR, Coco BJ, Patterson TF (2006) Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 50:1567-1569 doi: 10.1128/AAC.50.4.1567-1569.2006
20. Kontoyiannis DP, Hachem R, Lewis RE et al (2003) Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98:292-299 doi: 10.1002/cncr.11479
21. Kontoyiannis DP, Lewis RE, Sagar N et al (2000) Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: An E-test-based strategy. Antimicrob Agents Chemother 44:2915-2918 doi: 10.1128/AAC.44.10.2915-2918.2000
22. Lin MT, Lu HC, Chen WL (2001) Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis 33:1621-1627 doi: 10.1086/322631
23. Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32:358-366 doi: 10.1086/318483
24. Maertens J, Glasmacher A, Herbrecht R et al (2006) Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107:2888-2897 doi: 10.1002/cncr.22348
25. Maertens J, Raad I, Petrikkos G et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563-1571 doi: 10.1086/423381
26. Maertens J, Verhaegen J, Lagrou K et al (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood 97:1604-1610 doi: 10.1182/blood.V97.6.1604
27. Marr KA, Boeckh M, Carter RA et al (2004) Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39:797-802 doi: 10.1086/ 423380
28. Marr KA, Carter RA, Crippa F et al (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909-917 doi: 10.1086/339202
29. Metcalf SC, Dockrell DH (2007) Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 55:287-299 doi: 10.1016/j.jinf.2007.06.012
30. Obayashi T, Yoshida M, Mori T et al (1995) Plasma (1®3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345:17-20 doi: 10.1016/ S0140-6736(95)91152-9
31. Pahls S, Schaffner A (1994) Aspergillus fumigatus pneumonia in neutropenic patients receiving fluconazole for infection due to Candida species: Is amphotericin B combined with fluconazole the appropriate answer. Clin Infect Dis 18:484-486
32. Patterson TF (2005) Advances and challenges in management of invasive mycoses. Lancet 366:1013-1025 doi: 10.1016/S0140-6736(05)67381-3
33. Schaffner A, Bohler A (1993) Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism. Mycoses 36:421-424
34. Shaukat A, Bakri F, Young P et al (2005) Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: Clinical, radiologic, and pathologic characteristics. Mycopathologia 159:181-188 doi: 10.1007/ s11046-004-5495-0
35. White PL, Linton CJ, Perry MD et al (2006) The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 42:479-486 doi: 10.1086/499949
36. Yoshida M, Tsubaki K, Kobayashi T et al (1999) Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991. Int J Hematol 70:261-267